Thursday, August 23, 2012
A team from the Crucell Vaccine Institute and The Scripps Research Institute has identified a trio of neutralizing human mAbs that
protect mice from challenge with influenza viruses, including one mAb that
protects against both A and B strains.1 Crucell N.V.,
first plans to develop the antibodies to treat influenza-infected individuals
and in the long run could use the antibody against A and B strains as a guide
for developing a universal influenza vaccine.
Entering the pipeline
The universe and everything
Baas, T. SciBX 5(33); doi:10.1038/scibx.2012.859
Published online Aug. 23, 2012
1. Dreyfus, C. et al.
Science; published online Aug. 9, 2012; doi:10.1126/science.1222908
Contact: Jaap Goudsmit, Crucell Vaccine Institute, Leiden,
2. Thompson, W.W. et
al. JAMA 292, 1333-1340 (2004)
C.S. & Levin, M.J. Hum. Vaccin. Immunother. 8, 81-88 (2012)
AND INSTITUTIONS MENTIONED
Biota Holdings Ltd. (ASX:BTA), Notting Hill, Victoria, Australia
Celltrion Inc. (KOSDAQ:068270), Incheon, South Korea
Crucell N.V. (Pink:CRXLY), Leiden, the Netherlands
Crucell Vaccine Institute, Leiden, the Netherlands
GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K.
Humabs BioMed S.A., Bellizona, Switzerland
Institute for Research in Biomedicine, Bellizona, Switzerland
Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J.
Mount Sinai School of Medicine, New York, N.Y.
National Institutes of Health, Bethesda, Md.
The Scripps Research Institute, La Jolla, Calif.